<DOC>
	<DOCNO>NCT01089452</DOCNO>
	<brief_summary>This study look evaluate drug combination , olmesartan/amlodipine perindopril/amlodipine , good lower blood pressure people mild moderate hypertension . The investigator enrol people either currently take medication low blood pressure recently diagnose high blood pressure yet medication . Patients medication blood pressure ask stop take medication 2 4 week . If blood pressure suitable ( high low ) randomise one treatment arm : Group 1 receive Perindopril ( 5mg 4 week follow 10mg 8 week ) . There 80 patient group . Group 2 receive Perindopril Amlodipine together ( 5mg/5mg 4 week , 10mg/5mg 4 week 10mg/10mg final 4 week ) . There 80 patient group . Group 3 receive Olmesartan Amlodipine together ( 20mg/5mg 4 week , 40mg/5mg 4 week 40mg/10mg final 4 week ) . There 120 patient group . During study measure patient blood pressure heart rate , weight perform routine blood test . They also ECGs ( 3 occasion ) 24 hour blood pressure monitor ( 4 occasion ) . At end study patient pre-study medication restart put suitable alternative .</brief_summary>
	<brief_title>Angiotensin Receptor Blocker Combined With Calcium Antagonist Evaluation Safety Lowering Systolic Blood Pressure Study</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Perindopril</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>1 . Over 18 year age 2 . Has provide write informed consent 3 . Mild moderate hypertension ( WHO Stage 12 ) . Patients mild moderate hypertension either de novo presenter condition withdrawn background antihypertensive therapy period 2 week . If sSBP great 140 mmHg 2 week withdrawal period ( *130 mmHg diabetes CKD , per Heart Foundation Australia Hypertension Guidelines 20082 ) , patient follow , therapy , 2 week order meet criterion . If systolic blood pressure 180 mmHg withdrawn study provide appropriate treatment . 4 . Hypertensive patient high level risk , i.e . least one follow risk factor : History CV event eg MI , stroke ( &gt; 6 month ago ) History revascularization procedure ( &gt; 6 month ago ) Impaired kidney function ( eGFR &lt; 70 ml/min ) ECG echocardiographic evidence LV hypertrophy Obesity , define BMI &gt; 30 kg/m2 Diabetes mellitus Peripheral arterial disease Macroalbuminuria Current smoking ( define smoking least 7 cigarette per week ) 5 . Women must post menopausal use acceptable method contraception i.e . surgical sterilisation , hormonal contraception double barrier method . 1 . Secondary cause hypertension ( e.g . Conn 's Syndrome , renal artery stenosis ) 2 . Serum creatinine &gt; 0.25 mmol/L eGFR &lt; 40 ml/min 3 . Serum potassium &gt; 5.5 mmol/L 4 . Abnormal LFTs ( i.e . serum transaminases &gt; 2x ULN ) 5 . Sitting SBP &gt; 180 mmHg 6 . Recent ( &lt; 6 month ) MI , CVA , TIA , revascularisation procedure 7 . Ethanol abuse ( opinion investigator ) 8 . Concomitant drug therapy may impact BP e.g . NSAIDs , COX2 inhibitor , antihypertensive agent 9 . Unable comply study requirement ( opinion investigator ) 10 . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Mild moderate hypertension</keyword>
</DOC>